Banales, Jesus M. and Marin, Jose J. G. and Lamarca, Angela and Rodrigues, Pedro M. and Khan, Shahid A. and Roberts, Lewis R. and Cardinale, Vincenzo and Carpino, Guido and Andersen, Jesper B. and Braconi, Chiara and Calvisi, Diego F. and Perugorria, Maria J. and Fabris, Luca and Boulter, Luke and Macias, Rocio I. R. and Gaudio, Eugenio and Alvaro, Domenico and Gradilone, Sergio A. and Strazzabosco, Mario and Marzioni, Marco and Coulouarn, Cedric and Fouassier, Laura and Raggi, Chiara and Invernizzi, Pietro and Mertens, Joachim C. and Moncsek, Anja and Rizvi, Sumera and Heimbach, Julie and Koerkamp, Bas Groot and Bruix, Jordi and Forner, Alejandro and Bridgewater, John and Valle, Juan W. and Gores, Gregory J. (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 17 (9). pp. 557-588. ISSN 1759-5045, 1759-5053
Full text not available from this repository. (Request a copy)Abstract
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for similar to 15% of all primary liver cancers and similar to 3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing similar to 2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | BILIARY-TRACT CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; PRIMARY SCLEROSING CHOLANGITIS; MIXED HEPATOCELLULAR-CHOLANGIOCARCINOMA; HUMAN INTRAHEPATIC CHOLANGIOCARCINOMA; ISOCITRATE DEHYDROGENASE 1; CIRCULATING TUMOR-CELLS; STEM-LIKE PLASTICITY; BILE-DUCT CANCER; PERIHILAR CHOLANGIOCARCINOMA; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 22 Mar 2021 05:29 |
| Last Modified: | 22 Mar 2021 05:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/44337 |
Actions (login required)
 |
View Item |
